NCT04814771View on ClinicalTrials.gov

Mass Balance Study of TS-142 in Healthy Adult Subjects.

PHASE1CompletedINTERVENTIONAL
Enrollment

6

Participants

Timeline

Start Date

April 19, 2021

Primary Completion Date

May 19, 2021

Study Completion Date

May 19, 2021

Conditions
Healthy Male Subjects
Interventions
DRUG

[14C] TS-142

Subjects received single dose of 7.5 mg of TS-142 containing 20 kBq \[14C\]TS-142 as an oral solution

Trial Locations (1)

Unknown

Taisho Pharmaceutical Co., Ltd selected site, Tokyo

All Listed Sponsors
lead

Taisho Pharmaceutical Co., Ltd.

INDUSTRY